Molindone Hydrochloride may be available in the countries listed below.
Molindone Hydrochloride (BANM, USAN) is known as Molindone in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| USAN | United States Adopted Name |
DIANEAL Low Calcium peritoneal dialysis solutions in AMBU-FLEX containers are sterile, nonpyrogenic solutions for intraperitoneal administration only. They contain no bacteriostatic or antimicrobial agents or added buffers.
Composition, calculated osmolarity, pH and ionic concentrations are shown in Table 1.
Potassium is omitted from peritoneal dialysis solutions because dialysis may be performed to correct hyperkalemia. In situations in which there is a normal serum potassium level or hypokalemia, the addition of potassium chloride (up to a concentration of 4 mEq/L) may be indicated to prevent severe hypokalemia. Addition of potassium chloride should be made after careful evaluation of serum and total body potassium and only under the direction of a physician. Frequent monitoring of serum electrolytes is indicated.
In some patients calcium carbonate is used as a phosphate binder. Because serum calcium levels have been observed to be elevated in these patients (Slatopolsky et al. 1986), the calcium concentration of DIANEAL Low Calcium peritoneal dialysis solutions has been reduced to 2.5 mEq/L. Serum calcium levels should be monitored and if low, the amount of oral calcium carbonate phosphate binder may be increased or peritoneal dialysis solutions containing higher calcium concentrations may be used. If serum calcium levels rise, adjustments to the dosage of the calcium carbonate phosphate binder and/or vitamin D analogs should be considered by the physician.
Because average plasma magnesium levels in some chronic CAPD patients have been observed to be elevated (Nolph et al. 1981), the magnesium concentration of this formulation has been reduced to 0.5 mEq/L. Average plasma magnesium levels have not been reported for chronic IPD and CCPD patients. Serum magnesium levels should be monitored and if low, oral magnesium supplements, oral magnesium containing phosphate binders, or peritoneal dialysis solutions containing higher magnesium concentrations may be used.
Because average serum bicarbonate levels in some chronic CAPD patients (Nolph et al. 1981), some chronic IPD patients (La Greca et al. 1980), and some chronic CCPD patients (Diaz-Buxo et al. 1983), have been observed to be somewhat lower than normal values, the bicarbonate precursor (lactate) concentration of DIANEAL Low Calcium peritoneal dialysis solutions has been raised to 40 mEq/L. Serum bicarbonate levels should be monitored.
The osmolarities shown in Table 1 are calculated values. Calculated osmolarity of DIANEAL Low Calcium peritoneal dialysis solution with 1.5% dextrose is 344 mOsmol/L, compared with measured values in normal human serum of 280 mOsmol/L.
The plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overpouch is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
Peritoneal dialysis is a procedure for removing toxic substances and metabolites normally excreted by the kidneys, and for aiding in the regulation of fluid and electrolyte balance.
The procedure is accomplished by instilling peritoneal dialysis fluid through a conduit into the peritoneal cavity. With the exception of lactate, present as a bicarbonate precursor, electrolyte concentrations in the fluid have been formulated in an attempt to normalize plasma electrolyte concentrations resulting from osmosis and diffusion across the peritoneal membrane (between the patient’s plasma and the dialysis fluid). Toxic substances and metabolites, present in high concentrations in the blood, cross the peritoneal membrane into the dialyzing fluid. Dextrose in the dialyzing fluid is used to produce a solution hyperosmolar to the plasma, creating an osmotic gradient which facilitates fluid removal from the patient’s plasma into the peritoneal cavity. After a period of time (dwell time), the fluid is drained from the cavity.
DIANEAL Low Calcium peritoneal dialysis solutions are indicated for use in chronic renal failure patients being maintained on peritoneal dialysis.
None known.
Peritoneal dialysis should be done with great care, if at all, in patients with a number of abdominal conditions including disruption of the peritoneal membrane or diaphragm by surgery or trauma, extensive adhesions, bowel distention, undiagnosed abdominal disease, abdominal wall infection, hernias or burns, fecal fistula or colostomy, tense ascites, obesity, and large polycystic kidneys (Vaamonde and Perez 1977). Other conditions include recent aortic graft replacement and severe pulmonary disease. When assessing peritoneal dialysis as the mode of therapy in such extreme situations, the benefits to the patient must be weighed against the possible complications.
An accurate fluid balance record must be kept and the weight of the patient carefully monitored to avoid over or under hydration with severe consequences including congestive heart failure, volume depletion, and shock.
Excessive use of DIANEAL Low Calcium peritoneal dialysis solution with 3.5% or 4.25% dextrose during a peritoneal dialysis treatment can result in significant removal of water from the patient.
Stable patients undergoing maintenance peritoneal dialysis should have routine periodic evaluation of blood chemistries and hematologic factors, as well as other indicators of patient status.
In some patients calcium carbonate is used as a phosphate binder. Because serum calcium levels have been observed to be elevated in these patients (Slatopolsky et al. 1986), the calcium concentration of DIANEAL Low Calcium peritoneal dialysis solutions has been reduced to 2.5 mEq/L. Serum calcium levels should be monitored and if low, the amount of oral calcium carbonate phosphate binder may be increased or peritoneal dialysis solutions containing higher calcium concentrations may be used. If serum calcium levels rise, adjustments to the dosage of the calcium carbonate phosphate binder and/or vitamin D analogs should be considered by the physician.
Because average plasma magnesium levels in some chronic CAPD patients have been observed to be elevated (Nolph et al. 1981), the magnesium concentration of this formulation has been reduced to 0.5 mEq/L. Average plasma magnesium levels have not been reported for chronic IPD and CCPD patients. Serum magnesium levels should be monitored and if low, oral magnesium supplements, oral magnesium containing phosphate binders, or peritoneal dialysis solutions containing higher magnesium concentrations may be used.
Because average serum bicarbonate levels in some chronic CAPD patients (Nolph et al. 1981), some chronic IPD patients (La Greca et al. 1980), and some chronic CCPD patients (Diaz-Buxo et al. 1983), have been observed to be somewhat lower than normal values, the bicarbonate precursor (lactate) concentration of DIANEAL Low Calcium peritoneal dialysis solutions has been raised to 40 mEq/L. Serum bicarbonate levels should be monitored.
Not for use in the treatment of lactic acidosis.
Potassium is omitted from DIANEAL Low Calcium peritoneal dialysis solutions because dialysis may be performed to correct hyperkalemia. Addition of potassium chloride should be made after careful evaluation of serum and total body potassium and only under the direction of a physician.
The use of 5 or 6 liters of dialysis solution is not indicated in a single exchange.
Refer to manufacturer’s directions accompanying drugs to obtain full information on additives.
If the resealable rubber plug on the medication port is missing or partially removed, do not use product if medication is to be added.
After the pull ring has been removed, inspect connector of solution container for fluid flow. A few drops of solution within the connector or pull ring may be present due to condensation of water resulting from the sterilization process. If a continuous stream of fluid is noted, discard solution because sterility may be impaired.
After removing overpouch, check for minute leaks by squeezing container firmly. If leaks are found, discard the solution because the sterility may be impaired.
Freezing of solution may occur at temperatures below 0°C (32°F). Allow to thaw naturally in ambient conditions and thoroughly mix contents by shaking.
Aseptic technique must be used throughout the procedure and at its termination in order to reduce the possibility of infection. If peritonitis occurs, the choice and dosage of antibiotics should be based upon the results of identification and sensitivity studies of the isolated organism(s) when possible. Prior to identification of the involved organism(s), broad-spectrum antibiotics may be indicated.
Peritoneal dialysis solutions may be warmed in the overpouch to 37°C (98.6°F) to enhance patient comfort. However, only dry heat (for example, heating pad) should be used. Solutions should not be heated in water due to an increased risk of infection. Microwave ovens should not be used to heat solutions because there is a potential for damage to the solution container. Moreover, microwave oven heating may potentially cause overheating and/or non-uniform heating of the solution that may result in patient injury or discomfort.
Significant losses of protein, amino acids and water soluble vitamins may occur during peritoneal dialysis. Replacement therapy should be provided as necessary.
Animal reproduction studies have not been conducted with DIANEAL Low Calcium peritoneal dialysis solutions. It is also not known whether DIANEAL Low Calcium peritoneal dialysis solutions can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. DIANEAL Low Calcium peritoneal dialysis solutions should be given to a pregnant woman only if clearly needed.
Do not administer unless solution is clear and seal is intact.
Adverse reactions to peritoneal dialysis include mechanical and solution related problems as well as the results of contamination of equipment or improper technique in catheter placement. Abdominal pain, bleeding, peritonitis, subcutaneous infection around a chronic peritoneal catheter, catheter blockage, difficulty in fluid removal, and ileus are among the complications of the procedure. Solution related adverse reactions may include electrolyte and fluid imbalances, hypovolemia, hypervolemia, hypertension, hypotension, disequilibrium syndrome, and muscle cramping.
When prescribing the solution to be used for an individual patient, consideration should be given to the potential interaction between the dialysis treatment and therapy directed at other existing illnesses. For example, rapid potassium removal may create arrhythmias in cardiac patients using digitalis or similar drugs; digitalis toxicity may be masked by elevated potassium or magnesium, or by hypocalcemia. Correction of electrolytes by dialysis may precipitate signs and symptoms of digitalis excess. Conversely, toxicity may occur at suboptimal dosages of digitalis if potassium is low or calcium high. Azotemic diabetics require careful monitoring of insulin requirements during and following dialysis with dextrose containing solutions.
DIANEAL Low Calcium peritoneal dialysis solutions are intended for intraperitoneal administration only.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
The mode of therapy (Intermittent Peritoneal Dialysis [IPD], Continuous Ambulatory Peritoneal Dialysis [CAPD], or Continuous Cyclic Peritoneal Dialysis [CCPD]), frequency of treatment, formulation, exchange volume, duration of dwell, and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient.
To avoid the risk of severe dehydration and hypovolemia and to minimize the loss of protein, it is advisable to select the peritoneal dialysis solution with the lowest level of osmolarity consistent with the fluid removal requirements for that exchange.
Peritoneal dialysis solutions may be warmed in the overpouch to 37°C (98.6°F) to enhance patient comfort. However, only dry heat (for example, heating pad) should be used. (See Directions for Use)
The addition of heparin to the dialysis solution may be indicated to aid in prevention of catheter blockage in patients with peritonitis, or when the solution drainage contains fibrinous or proteinaceous material (Ribot et al. 1966). 1000 to 2000 USP units of heparin per liter of solution has been recommended for adults (Furman et al. 1978). For children, 50 units of heparin per 100 mL of dialysis fluid has been recommended (Irwin et al. 1981).
Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.
For maintenance dialysis of chronic renal failure patients.
The cycle of instillation, dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week as indicated by the condition of the patient. For chronic renal failure patients, maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) (Mattocks and El-Bassiouni 1971).
For maintenance dialysis of chronic renal failure patients.
In CAPD, typically 1.5 to 3.0 liters of dialysis solution (depending upon patient size) are instilled into the peritoneal cavity of adults and the peritoneal access device is then clamped (Kim et al. 1984; Twardowski and Janicka 1981; Twardowski and Burrows 1984). For children, 30 to 50 mL/kg body weight with a maximum of 2 liters has been recommended (Potter et al. 1981; Irwin et al. 1981). The solution remains in the cavity for dwell times of 4 to 8 hours during the day and 8 to 12 hours overnight. At the conclusion of each dwell period, the access device is opened, the solution drained and fresh solution instilled. The procedure is repeated 3 to 5 times per day, 6 to 7 days per week. Solution exchange volumes and frequency of exchanges should be individualized for adequate biochemical and fluid volume control (Moncrief et al. 1982; Twardowski et al. 1983). The majority of exchanges will utilize 1.5% or 2.5% dextrose containing peritoneal dialysis solutions, with 3.5% or 4.25% dextrose containing solutions being used when extra fluid removal is required. Patient weight is used as the indicator of the need for fluid removal (Popovich et al. 1978).
In CCPD, the patient receives 3 or 4 dialysis exchanges during the night which range from 2-1/2 to 3 hours dwell duration. Typically 1.5 to 2.0 liters of dialysis solution (depending upon patient size) are delivered each cycle by an automatic peritoneal dialysis cycler machine. After the last outflow during the night, an additional exchange is infused by the cycler machine into the peritoneum. The equipment is then disconnected from the patient, and the dialysate remains in the peritoneum for 14 to 15 hours during the day until the next nocturnal cycle (Diaz-Buxo et al. 1981). Combinations of 1.5% or 2.5% dextrose containing peritoneal dialysis solutions are usually used for the nighttime exchanges, while 3.5% or 4.25% dextrose containing solution is used when extra fluid removal is required such as during the daytime exchange. Patient weight is used as the indicator of the need for fluid removal (Popovich et al. 1978) so therapy should be individualized according to the patient’s need for ultrafiltration.
It is recommended that adult patients being placed on peritoneal dialysis or, in the case of pediatric patients, the selected caretaker, (as well as the patient, when suitable), should be appropriately trained in a program which is under the supervision of a physician. Training materials are available from Baxter Healthcare Corporation, Deerfield, IL 60015 USA to facilitate this training.
DIANEAL Low Calcium peritoneal dialysis solutions in AMBU-FLEX II and AMBU-FLEX III containers are available in nominal size flexible containers with fill volumes as indicated in Table 1.
All DIANEAL Low Calcium peritoneal dialysis solutions have overfills which are declared on container labeling.
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C/77°F): brief exposure up to 40°C (104°F) does not adversely affect the product.
Use aseptic technique.
For complete system preparation, see directions accompanying ancillary equipment.
Peritoneal dialysis solutions may be warmed in the overpouch to 37°C (98.6°F) to enhance patient comfort. However, only dry heat (for example, heating pad) should be used. Solutions should not be heated in water due to an increased risk of infection. Microwave ovens should not be used to heat solutions because there is a potential for damage to the solution container. Moreover, microwave oven heating may potentially cause overheating and/or non-uniform heating of the solution that may result in patient injury or discomfort.
Tear overpouch down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. If supplemental medication is desired, follow directions below before preparing for administration. Check for minute leaks by squeezing container firmly.
Additives may be incompatible.
If the resealable rubber plug on the medication port is missing or partially removed, do not use product if medication is to be added.
| Table 1 | ||||||||||||||||
| Composition/100mL | OSMOLARITY (mOsmol/L) (calc) | pH | Ionic Concentration (mEq/L) | How Supplied | ||||||||||||
| *Dextrose, Hydrous, USP | Sodium Chloride, USP (NaCl) | Sodium Lactate (C3H5NaO3) | Calcium Chloride, USP (CaCl2•2H2O) | Magnesium Chloride, USP (MgCl2•6H2O) | Sodium | Calcium | Magnesium | Chloride | Lactate | Fill Volume (mL) | Container Size (mL) | Code | NDC | |||
| DIANEAL Low Calcium Peritoneal Dialysis Solution with 1.5% Dextrose AMBU-FLEX II Container | 1.5 g | 538 mg | 448 mg | 18.3 mg | 5.08 mg | 344 | 5.2 (4.0 to 6.5) | 132 | 2.5 | 0.5 | 95 | 40 | 2000 2500 3000 5000 6000 | 3000 3000 3000 6000 6000 | L5B4825 L5B9718 L5B9901 L5B4826 L5B9770 | NDC 0941-0409-06 NDC 0941-0409-08 NDC 0941-0409-05 NDC 0941-0409-07 NDC 0941-0409-01 |
| DIANEAL Low Calcium Peritoneal Dialysis Solution with 1.5% Dextrose AMBU-FLEX III Container | 1.5 g | 538 mg | 448 mg | 18.3 mg | 5.08 mg | 344 | 5.2 (4.0 to 6.5) | 132 | 2.5 | 0.5 | 95 | 40 | 1500 2000 2500 3000 5000 6000 | 2000 2000 3000 3000 5000 6000 | 5B9715 5B4825 5B9718 5B9901 5B4826 5B9770 | NDC 0941-0409-45 NDC 0941-0409-36 NDC 0941-0409-48 NDC 0941-0409-49 NDC 0941-0409-27 NDC 0941-0409-28 |
| DIANEAL Low Calcium Peritoneal Dialysis Solution with 2.5% Dextrose AMBU-FLEX II Container | 2.5 g | 538 mg | 448 mg | 18.3 mg | 5.08 mg | 395 | 5.2 (4.0 to 6.5) | 132 | 2.5 | 0.5 | 95 | 40 | 2000 2500 3000 5000 6000 | 3000 3000 3000 6000 6000 | L5B9727 L5B9728 L5B9902 L5B5202 L5B9771 | NDC 0941-0457-08 NDC 0941-0457-07 NDC 0941-0457-02 NDC 0941-0457-05 NDC 0941-0457-01 |
| DIANEAL Low Calcium Peritoneal Dialysis Solution with 2.5% Dextrose AMBU-FLEX III Container | 2.5 g | 538 mg | 448 mg | 18.3 mg | 5.08 mg | 395 | 5.2 (4.0 to 6.5) | 132 | 2.5 | 0.5 | 95 | 40 | 1500 2000 2500 3000 5000 6000 | 2000 3000 3000 3000 5000 6000 | 5B9725 5B9727 5B9728 5B9902 5B5202 5B9771 | NDC 0941-0457-45 NDC 0941-0457-47 NDC 0941-0457-48 NDC 0941-0457-49 NDC 0941-0457-25 NDC 0941-0457-28 |
| DIANEAL Low Calcium Peritoneal Dialysis Solution with 3.5% Dextrose AMBU-FLEX III Container | 3.5 g | 538 mg | 448 mg | 18.3 mg | 5.08 mg | 445 | 5.2 (4.0 to 6.5) | 132 | 2.5 | 0.5 | 95 | 40 | 2500 | 3000 | 5B9738 | NDC 0941-0463-48 |
| DIANEAL Low Calcium Peritoneal Dialysis Solution with 4.25% Dextrose AMBU-FLEX II Container | 4.25 g | 538 mg | 448 mg | 18.3 mg | 5.08 mg | 483 | 5.2 (4.0 to 6.5) | 132 | 2.5 | 0.5 | 95 | 40 | 2000 2500 3000 5000 6000 | 3000 3000 3000 6000 6000 | L5B9747 L59B748 L5B9903 L5B5203 L5B9772 | NDC 0941-0459-08 NDC 0941-0459-07 NDC 0941-0459-02 NDC 0941-0459-05 NDC 0941-0459-01 |
| DIANEAL Low Calcium Peritoneal Dialysis Solution with 4.25% Dextrose AMBU-FLEX III Container | 4.25 g | 538 mg | 448 mg | 18.3 mg | 5.08 mg | 483 | 5.2 (4.0 to 6.5) | 132 | 2.5 | 0.5 | 95 | 40 | 1500 2000 2500 3000 5000 6000 | 2000 3000 3000 3000 5000 6000 | 5B9745 5B9747 5B9748 5B9903 5B5203 5B9772 | NDC 0941-0459-45 NDC 0941-0459-47 NDC 0941-0459-48 NDC 0941-0459-49 NDC 0941-0459-25 NDC 0941-0459-28 |
Baxter, DIANEAL, AMBU-FLEX, and PL 146 are trademarks of
Baxter International Inc.
Baxter Healthcare Corporation
Deerfield, IL 60015 USA
Printed in USA
©Copyright 1981, 1982, 1983, 1984, 1989, 2008 Baxter Healthcare Corporation.
All rights reserved.
07-19-60-956
2009/08
Container Label
5B4825
NDC 0941-0409-36
2000 mL
(APPROX 80 mL EXCESS)
Baxter
Dianeal
Low Calcium (2.5 mEq/L)
Peritoneal Dialysis Solution
with 1.5% Dextrose
Low Calcium 1.5% Dextrose
EACH 100 mL CONTAINS 1.5 g DEXTROSE HYDROUS USP
538 mg SODIUM CHLORIDE USP 448 mg SODIUM
LACTATE 18.3 mg CALCIUM CHLORIDE USP 5.08 mg
MAGNESIUM CHLORIDE USP pH 5.2 (4.0 TO 6.5)
mEq/L SODIUM - 132 CALCIUM - 2.5 MAGNESIUM -
0.5 CHLORIDE - 95 LACTATE - 40
OSMOLARITY - 344 mOsmol/L (CALC)
STERILE NONPYROGENIC
POTASSIUM CHLORIDE TO BE ADDED ONLY
UNDER THE DIRECTION OF A PHYSICIAN
READ PACKAGE INSERT FOR FULL INFORMATION
FOR INTRAPERITONEAL ADMINISTRATION ONLY
DOSAGE AS DIRECTED BY A PHYSICIAN
CAUTIONS SQUEEZE AND INSPECT INNER BAG
WHICH MAINTAINS PRODUCT STERILITY DISCARD
IF LEAKS ARE FOUND
DO NOT USE UNLESS SOLUTION IS CLEAR
DISCARD UNUSED PORTION
Rx ONLY
STORE UNIT IN MOISTURE BARRIER OVERWRAP AT
ROOM TEMPERATURE (25°C/77°F) UNTIL READY TO
USE
AVOID EXCESSIVE HEAT SEE INSERT
Ambu-Flex III CONTAINER PL 146 PLASTIC
BAXTER DIANEAL AMBU-FLEX III AND PL 146 ARE
TRADEMARKS OF BAXTER INTERNATIONAL INC
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
US PAT NO 4573980
Carton Label
5B4825
6-2000 ML
AMBU-FLEXTM III CONTAINERS
1.5%
DIANEAL® LOW CALCIUM 1.5% DEX
PERITONEAL DIALYSIS SOLUTION
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50309410409362
| DIANEAL LOW CALCIUM PERITONEAL DIALYSIS SOLUTION WITH DEXTROSE sodium chloride, sodium lactate, calcium chloride, magnesium chloride and dextrose injection, solution | ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA017512 | 01/10/1989 | |
| DIANEAL LOW CALCIUM PERITONEAL DIALYSIS SOLUTION WITH DEXTROSE sodium chloride, sodium lactate, calcium chloride, magnesium chloride and dextrose injection, solution | ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA017512 | 01/10/1989 | |
Siopelmin may be available in the countries listed below.
Nifedipine is reported as an ingredient of Siopelmin in the following countries:
International Drug Name Search
Hidrocortisona GP Pharm may be available in the countries listed below.
Hydrocortisone is reported as an ingredient of Hidrocortisona GP Pharm in the following countries:
International Drug Name Search
Venlafaxin Hennig may be available in the countries listed below.
Venlafaxine hydrochloride (a derivative of Venlafaxine) is reported as an ingredient of Venlafaxin Hennig in the following countries:
International Drug Name Search
Glicerolo + Sodio Cloruro Fresenius may be available in the countries listed below.
Glycerol is reported as an ingredient of Glicerolo + Sodio Cloruro Fresenius in the following countries:
International Drug Name Search
Levadin may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Levamisole is reported as an ingredient of Levadin in the following countries:
Levamisole hydrochloride (a derivative of Levamisole) is reported as an ingredient of Levadin in the following countries:
International Drug Name Search
In the US, Orthoclone OKT3 (muromonab-cd3 systemic) is a member of the drug class selective immunosuppressants and is used to treat Rejection Prophylaxis and Rejection Reversal.
US matches:
Muromonab-CD3 is reported as an ingredient of Orthoclone OKT3 in the following countries:
International Drug Name Search
Pethidine Hydrochloride may be available in the countries listed below.
Pethidine Hydrochloride (BANM, JAN) is also known as Pethidine (Rec.INN)
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| JAN | Japanese Accepted Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
RG-Q may be available in the countries listed below.
Tocopherol, α- is reported as an ingredient of RG-Q in the following countries:
Ubidecarenone is reported as an ingredient of RG-Q in the following countries:
International Drug Name Search
Citalec Zentiva may be available in the countries listed below.
Citalopram hydrobromide (a derivative of Citalopram) is reported as an ingredient of Citalec Zentiva in the following countries:
International Drug Name Search
Triplegard may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Dimpylate is reported as an ingredient of Triplegard in the following countries:
Pyriproxyfen is reported as an ingredient of Triplegard in the following countries:
International Drug Name Search
Ritonax may be available in the countries listed below.
Ritonavir is reported as an ingredient of Ritonax in the following countries:
International Drug Name Search
Miopropan may be available in the countries listed below.
Trimebutine maleate (a derivative of Trimebutine) is reported as an ingredient of Miopropan in the following countries:
International Drug Name Search
Hibiscrud may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Hibiscrud in the following countries:
International Drug Name Search
Prussian Blue insoluble may be available in the countries listed below.
Prussian Blue insoluble (USAN) is known as Prussian Blue in the US.
International Drug Name Search
Glossary
| USAN | United States Adopted Name |
